Nuñez, Nicolas A.
Coombes, Brandon J. http://orcid.org/0000-0003-4322-5923
Beaupre, Lindsay Melhuish
Ozerdem, Aysegul
Resendez, Manuel Gardea
Romo-Nava, Francisco
Bond, David J.
Veldic, Marin http://orcid.org/0000-0002-7651-9197
Singh, Balwinder http://orcid.org/0000-0001-7062-8192
Moore, Katherine M.
Betcher, Hannah K.
Kung, Simon
Prieto, Miguel L.
Fuentes, Manuel
Ercis, Mete http://orcid.org/0000-0003-1272-5503
Miola, Alessandro
Sanchez Ruiz, Jorge A. http://orcid.org/0000-0003-4282-7359
Jenkins, Gregory http://orcid.org/0000-0001-6408-6227
Batzler, Anthony
Leung, Jonathan G. http://orcid.org/0000-0003-3836-9375
Cuellar-Barboza, Alfredo http://orcid.org/0000-0002-7663-913X
Tye, Susannah J. http://orcid.org/0000-0003-1291-4304
McElroy, Susan L.
Biernacka, Joanna M. http://orcid.org/0000-0001-9350-4440
Frye, Mark A. http://orcid.org/0000-0001-6997-4215
Article History
Received: 9 June 2023
Revised: 8 January 2024
Accepted: 17 January 2024
First Online: 13 February 2024
Competing interests
: NAN reports no financial relationships with commercial interests. BJC reports no financial relationships with commercial interests. LMB reports no financial relationships with commercial interests. AO reports no financial relationships with commercial interests. MGR reports no financial relationships with commercial interests. FRN receives grant support from the National Institute of Mental Health K23 Award (K23MH120503) and from a 2017 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation; has a U.S. Patent and Trademark Office patent # 10,857,356; receives consultant fees from Otsuka Pharmaceutical and has received non-financial research support from Soterix Medical. DJB has received research support from NIDA, NuBiyota, the University of Minnesota Foundation, and the University of Minnesota Department of Psychiatry and Behavioral Sciences MV reports no financial relationships with commercial interests. BS received grant support from Mayo Clinic. KMM reports no financial relationships with commercial interests. HKB reports no financial relationships with commercial interests. SK reports no financial relationships with commercial interests. MFS reports no financial relationships with commercial interests. ME reports no financial relationships with commercial interests. AM reports no financial relationships with commercial interests. JASR reports no financial relationships with commercial interests. GJ reports no financial relationships with commercial interests. AB reports no financial relationships with commercial interests. JGL reports no financial relationships with commercial interests. ACB reports no financial relationships with commercial interests. SJT reports no financial relationships with commercial interests. SLM is or has been a consultant to or member of the scientific advisory boards of Avanir, Allergan (now AbbVie), Bracket (now Signant Health), Idorsia, Intra-Cellular Therapies, Inc., Naurex, Otsuka, Shire (now Takeda), Sunovion, and Takeda. She is or has been a principal or co-investigator on studies sponsored by the Agency for Healthcare Research & Quality (AHRQ), Avenir, AstraZeneca, Cephalon, Forest, Jazz, Marriott Foundation, Medibio, National Institute of Mental Health, Orexigen Therapeutics, Inc., Otsuka, Shire (now Takeda), Sunovian, and Takeda Pharmaceutical Company Ltd. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent. JMB reports no financial relationships with commercial interests. MAF has received grant support from Assurex Health and Mayo Foundation, received CME travel and honraria from Carnot Laboratories, and has Financial Interest/Stock ownership/Royalties from Chymia LLC.